Navigation Links
Stem Cell Markets - 2013 Report Examines the Use of Stem Cells in Developing New Therapies for Disease
Date:11/20/2013

DUBLIN, Ireland, November 20, 2013 /PRNewswire/ --

Research and Markets
( http://www.researchandmarkets.com/research/59bkth/stem_cell_markets) has announced the addition of the "Stem Cell Markets" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)


A stem cell is an extraordinary type of cell that has the ability to self-renew for long periods of time and to differentiate into specialized cells under appropriate physiological or experimental conditions. Traditionally, stem cells have been classified as either embryonic, adult (tissue-specific or cord blood) stem cells.

Recent understanding of stem cell biology may provide new approaches for the treatment of a number of diseases as well as tissue/organ injuries, including cardiovascular disease, neurological disease, musculoskeletal disease, diabetes and hematopoietic disorders. Stem cell fate is determined by both intrinsic regulators and the extra-cellular environment (niche), and their expansion and differentiation ex vivo are generally controlled by growing them in a specific configuration (monolayer or three-dimensional culture). This process, which is vital to enable stem cells to be used for therapeutic purposes, is called differentiation. Differentiation is a process involving unspecialized cells progressing to become specialized cells with restricted developmental potential.

The purpose of this report is to describe the specific market segments of the medical research space using stem cells for research and development (R&D) purposes. This study reviews all of the generally accepted analytical methods that are currently in use today for preparing and using stem cells.

Companies Mentioned:

- Aastrom Biosciences, Inc
- Athersys, Inc
- BD Biosciences
- Bioheart, Inc
- Brainstorm Cell Therapeutics, Inc
- Cardio3 BioSciences
- CryoLife, Inc
- Epistem PLC
- ES Cell International Pvt, Ltd
- Forticell Bioscience, Inc
- OrCel®
- Gamida Cell
- Humacyte, Inc
- Intercytex Group plc
- Japan Tissue Engineering Co., Ltd
- LifebankUSA
- Life Technologies Corporation
- Lonza
- MedCell Bioscience, Ltd
- Medistem, Inc
- Neostem, Inc
- Orthovita, Inc
- Osiris Therapeutics, Inc
- Pervasis Therapeutics, Inc
- Regenocyte Therapeutic
- Stempeutics Research Private Limited
- Tengion, Inc
- TheraVitae
- VistaGen Therapeutics, Inc
- ZenBio, Inc


For more information visit http://www.researchandmarkets.com/research/59bkth/stem_cell_markets

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Biotechnology



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
5. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
6. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
7. Animal Biotechnology - Technologies, Markets and Companies
8. Gene Therapy - Technologies, Markets and Companies
9. Biomarkers - Technologies, Markets and Companies
10. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
11. MarketsandMarkets: Chronic Lymphocytic Leukemia Therapeutics Market Worth $2.2 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):